Pennsylvania legislation · 2025-2026 Regular Session
Pennsylvania HB2270: An Act amending the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit Integrity and Transparency Act, in preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager.
Status: In committee, March 18, 2026
What the bill says
An act providing for pharmacy audit procedures, for registration of pharmacy benefits managers and auditing entities, for maximum allowable cost transparency, for prescription drugs reimbursed under the PACE and PACENET program and for pharmacy benefit managers contract requirements and prohibited activities; and making related repeals," in preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager.
From the introduced text, March 18, 2026:
An act providing for pharmacy audit procedures, for registration of pharmacy benefits managers and auditing entities, for maximum allowable cost transparency, for prescription drugs reimbursed under the PACE and PACENET program and for pharmacy benefit managers contract requirements and prohibited activities; and making related repeals," in preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. The definitions of "specialty drug" and "spread pricing" in section 103 of the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit Integrity and Transparency Act, added July 17, 2024 (P.L.852, No.77), are amended to read: Section 103. Definitions. The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise: * * * "Specialty drug." [Either of the following: (1) A prescription drug prescribed to a covered individual with a cost that meets or exceeds the cost of a drug on the specialty tier of Medicare Part D under 42 CFR 423.104(d)(2)(iv) (relating to requirements related to qualified prescription drug coverage) and meets three or more of the following criteria: (i) The drug requires specialized product handling or administration by the dispensing pharmacy. (ii) …